IDH1, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-IDH1, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | IDH1, Human |
| Clone | REAL1159 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | phycoerythrin (PE) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | IDH1 Antibody, anti-human, PE, REAdye_lease™. Clone REAL1159 is an antibody fragment derived from the full IDH1 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL1159 recognizes the IDH1 enzyme, also known as Isocitrate dehydrogenase (NADP) cytoplasmic, that plays an important role in lipid biosynthesis in different tissues such as the liver, adipose tissues, brain and tumors. Mutations of IDH is related to the progress and prognosis of certain tumors and have been found in numerous cancers, mainly in gliomas, chondrosarcomas or enchondromas, and cholangiocarcinomas. IDH1 is considered to be a specific biomarker for early diagnosis, prognosis and targeted therapy for tumors. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). | | |
| Immunogen | n/a |
| Other Names | Isocitrate dehydrogenase [NADP] cytoplasmic, IDH, IDP, Cytosolic NADP-isocitrate dehydrogenase, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase, PICD |
| Gene, Accession # | n/a |
| Catalog # | 130-130-129 |
| Price | $522 |
| Order / More Info | IDH1, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Dang, L. et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 739 (744): 462-7274. | Mondesir, J. et al. (2016) IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 7: 171-180. | Mehrjardi, M. Z. et al. (2020) Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma. Cell Death Dis 11 (11): 998. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG